Medical classes and syringes are marked with the NOVO NORDISK logo on the background screen.
NURPHOTO | NURPHOTO | Getty image
Denmark Pharmaceutical Giants said the next -generation weight loss drug CAGRIEMA helped adult patients who fell 15.7% of their weight after 68 weeks.
The company’s stock fell 6.3% at 11:22 am in London Time.
NOVO NORDISK, which manufactures fierce popular weight loss drug Wegovy, predicted 25% of patients who were previously taking CAGRISEMA. In another later trial published in December, the company helped CAGRISEMA helped the patient to reduce his weight by 22.7% in the test.
CAGRISEMA is a weight loss drug of adults that are overweight or obese by Novo Nordisk. The company currently expects to file a regulation approval for CAGRIEMA in the first quarter of 2026.
American rival stock Ellie LilyCreating a weight loss drug MOUNJARO has made a higher jump after the update of Novo Nordisk on Monday, but has dropped 1.2% from 11:34 am in London.
The market hopes that CAGRIEMA will be the next generation weight loss drug. The treatment once a week is the active ingredient of Wegovy, a combination of cagrilintide and semaglutide.
Cagriema’s three -phase test had 1,206 participants with an average weight weight of 102kg (225 LB).
Despite the negative response to the results of Monday investors, Novo Nordisk promoted a “excellent weight loss” achieved by those who took CAGRIEMA compared to those who had a 3.1%place of weight for 68 weeks.
Novo Nordisk also said that the drug seems to have a “safe and introverted profile”, and the most common side effects are mildness at moderate gastrointestinal symptoms. The company has declined over time, the company pointed out.
Last week, NOVO NORDISK started its online pharmacy, Novocare, allowing consumers to buy Wegovy directly from the company at $ 499 a month.
The success of weight loss drug Wegovy and Ozempic helped Novo Nordisk to become one of the most valuable companies in the world.
